Skip to content

Application of butorphanol tartrate combined with ropivacaine for preemptive analgesia at transversus abdominis plane block combined with rectus sheath block in gynecological laparoscopic surgery.

Application of butorphanol tartrate combined with ropivacaine for preemptive analgesia at transversus abdominis plane block combined with rectus sheath block in gynecological laparoscopic surgery.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300067579
Enrollment
Unknown
Registered
2023-01-12
Start date
2023-01-15
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gynecological diseases

Interventions

Composite Group (Group A):Butorphanol Tartrate Combined with Ropivacaine for transversus abdominis plane block combined with rectus sheath block
TAP+RSB Group (Group B):Ropivacaine for transversus abdominis plane block combined with rectus sheath block
General anesthesia Group (C Group):No transversus abdominis plane block combined with rectus sheath block

Sponsors

Heyuan People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Female patients undergoing gynecological laparoscopic surgery under general anesthesia; 2. The subjects were aged 18 to 65 years old and classified as I - II by ASA; 3. The body mass index (BMI) of 18-30 kg/m2.

Exclusion criteria

Exclusion criteria: 1. History of alcohol; 2. History of general or local anesthetic allergy; 3. Long-term use of Opioids; 4. History of unregulated or malignant hypertension; 5. Diabetes or severe ischemic heart diseases or renal or liver dysfunction; 6. Coagulation dysfunction or infection at puncture site; 7. Pregnancy or lactation; 8. Nervous system diseases or mental disorders with communication difficulties; 9. Operation time is more than 4 hours.

Design outcomes

Primary

MeasureTime frame
VAS of 2h after operation;

Secondary

MeasureTime frame
VAS and BCS at different time points after operation;Vital signs at different time points;Total Intraoperative Remifentanil Dosage;Incidence of adverse reactions after operation;

Countries

China

Contacts

Public ContactWenbo Huang

Heyuan People’s Hospital

913619449@qq.com13536776979

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026